7. FEJEZET | HIVATKOZÁSOK

  1. Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811-822.
  2. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.
  3. Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):
    1935-1939.
  4. Berntorp E. I mportance of rapid bleeding control in haemophilia complicated by inhibitors. Haemophilia. 2011;17(1):11-16.
  5. Aronstam A, Wassef M, Hamad Z, Cartlidge J, McLellan D. A double-blind controlled trial of two dose levels of factor VIII in the treatment of high risk haemarthroses in haemophilia A. Clin Lab Haematol. 1983;5(2):157-163.
  6. Aronstam A, Wasssef M, Choudhury DP, Turk PM, McLellan DS. Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A. Lancet. 1980;1(8161):169-171.
  7. Hermans C, De Moerloose P, Fischer K, et al. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia. 2011;17(3):383-392.
  8. Mathews V, Viswabandya A, Baidya S, et al. Surgery for hemophilia in developing countries. Semin Thromb Hemost. 2005;31(5):538-543.
  9. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia. 2006;12(5):514-517.
  10. Tsoukas C, Eyster ME, Shingo S, et al. Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. Blood. 2006;107(5):1785-1790.
  11. Eyster ME, Asaad SM, Gold BD, Cohn SE, Goedert JJ, Second Multicenter Hemophilia Study Group. Upper gastrointestinal bleeding in haemophiliacs: incidence and relation to use of non-steroidal anti-inflammatory drugs. Haemophilia. 2007;13(3):279-286.
  12. Stephensen D, Bladen M, McLaughlin P. Recent advances in musculoskeletal physiotherapy for haemophilia. Ther Adv Hematol. 2018;9(8):227-237.
  13. Lobet S, Hermans C, Lambert C. Optimal management of hemophilic arthropathy and hematomas. J Blood Med. 2014;5:207-218.
  14. Forsyth AL, Zourikian N, Valentino LA, Rivard GE. The effect of cooling on coagulation and haemostasis: should “Ice” be part of treatment of acute haemarthrosis in haemophilia? Haemophilia. 2012;18(6):843-850.
  15. Gilbert MS. Musculoskeletal complications of haemophilia: the joint. Haemophilia. 2000;6(Suppl 1):34-37.
  16. Blamey G, Forsyth A, Zourikian N, et al. Comprehensive elements of a physiotherapy exercise programme in haemophilia–a global perspective. Haemophilia. 2010;16(Suppl 5):136-145.
  17. Gomis M, Querol F, Gallach JE, Gonzalez LM, Aznar JA. Exercise and sport in the treatment of haemophilic patients: a systematic review. Haemophilia. 2009;15(1):43-54.
  18. Heijnen L, Buzzard BB. The role of physical therapy and rehabilitation in the management of hemofília in developing countries. Semin Thromb Hemost. 2005;31(5):513-517.
  19. Ingram GI, Mathews JA, Bennett AE. Controlled trial of joint aspiration in acute haemophilic haemarthrosis. A nn Rheum Dis. 1972;31(5):423.
  20. Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia. 2012;18(1):8-16.
  21. Srivasatava N, Shwarupa S, Bhagyawant SS. Comparative study on the anti-termite, antimicrobial and antioxidant activity of leaf and root extracts of Pothos aurea (Epipremnum aureum L.). JPRCP. 2011;1(2):1-11.
  22. Lj ung RC. I ntracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140(4):378-384.
  23. Nakar C, Cooper DL, DiMichele D. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (20042008). Haemophilia. 2010;16(4):625-631.
  24. Witmer CM, Manno CS, Butler RB, Raffini LJ. The clinical management of hemophilia and head trauma: a survey of current clinical practice among pediatric hematology/oncology physicians. Pediatr Blood Cancer. 2009;53(3):406-410.
  25. Traivaree C, Blanchette V, Armstrong D, Floros G, Stain AM, Carcao MD. Intracranial bleeding in haemophilia beyond the neonatal period– the role of CT imaging in suspected intracranial bleeding. Haemophilia. 2007;13(5):552-559.
  26. Patiroglu T, Ozdemir MA, Unal E, et al. Intracranial hemorrhage in children with congenital factor deficiencies. Childs Nerv Syst. 2011;27(11):
    1963-1966.
  27. Zanon E, Iorio A, Rocino A, et al. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia. 2012;18(1):39-45.
  28. Singleton T, Kruse-Jarres R, Leissinger C. Emergency department care for patients with hemophilia and von Willebrand disease. J Emerg Med. 2010;39(2):158-165.
  29. Bush MT, Roy N. Hemophilia emergencies. J Emerg Nurs. 1995;21(6):531-538; quiz 538-540.
  30. Guthrie TH Jr, Sacra JC. Emergency care of the hemophiliac patient. Ann Emerg Med. 1980;9(9):476-479.
  31. Kouides PA, Fogarty PF. How do we treat: upper gastrointestinal bleeding in adults with haemophilia. H aemophilia. 2010;16(2):360-362.
  32. Mittal R, Spero JA, Lewis JH, et al. Patterns of gastrointestinal hemorrhage in hemophilia. Gastroenterology. 1985;88(2):515-522.
  33. Quon DV, Konkle BA. How we treat: haematuria in adults with haemophilia. Haemophilia. 2010;16(4):683-685.
  34. Ghosh K, Jijina F, Mohanty D. Haematuria and urolithiasis in patients with haemophilia. Eur J Haematol. 2003;70(6):410-412.
  35. Kane MJ, Silverman LR, Rand JH, Paciucci PA, Holland JF. Myonecrosis as a complication of the use of epsilon aminocaproic acid: a case report and review of the literature. Am J Med. 1988;85(6):861-863.
  36. Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339(4):245-253.

TOVÁBBI INFORMÁCIÓ

További kiegészítő információk találhatóak online a További információk részben.